The Week of June 3 in Review
The week of June 3 in review, featuring content on crizotinib in NSCLC, an FDA approval, novel agents for the treatment of prostate cancer, and more.
Crizotinib Superior to Chemotherapy for Advanced ALK-Positive NSCLC
Crizotinib demonstrated superiority to chemotherapy for the treatment of previously treated, advanced non-small cell lung cancer (NSCLC) with ALK rearrangement in a trial published online by The New England Journal of Medicine on June 1.
Dr. Schuchter Gives an Overview of the Treatment of Melanoma
Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, gives an overview of the treatment of advanced melanoma at the 2013 ASCO Annual Meeting.
Lenalidomide Approved by the FDA for the Treatment of Mantle Cell Lymphoma
The immunomodulatory agent lenalidomide (Revlimid) has been approved by the FDA to treat patients with mantle cell lymphoma (MCL) who have relapsed or whose disease has progressed after two prior therapies including at least one prior treatment with bortezomib.
Dr. Neal D. Shore on the Approval of Radium-223
Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Myrtle Beach, comments on the impact of the approval of radium-223 for bone metastases from prostate cancer.
Case-Based Discussion: Integrating Novel Agents Into the Treatment of Prostate Cancer
In the wake of the approval of several novel treatments for prostate cancerincluding antiandrogens enzalutamide and abiraterone and immunotherapy sipuleucel-T, physicians must now focus on how best to integrate new therapies into the treatment of patients with prostate cancer.
Bundled Payment: Practice Savior or Killer?
The new “in” term among those looking to lower the cost of healthcare is “bundled payment” (BP). Although there is still disagreement about what it means, the bundling of payments revolves around oncologists being paid a set fee for managing their patients’ care.
Electra D. Paskett, PhD, on Vinegar as a Cervical Cancer Screening Tool
Electra D. Paskett, PhD, Professor, College of Medicine, The Ohio State University, describes the use of vinegar (acetic acid) as a cervical cancer screening tool.
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC
January 15th 2025During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.
Read More
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
